Spots Global Cancer Trial Database for ARQ 197 in Subjects With Metastatic Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: ARQ 197 in Subjects With Metastatic Solid Tumors
Official Title: A Phase 1 Dose Escalation Study of ARQ 197 in Adult Patients With Metastatic Solid Tumors
Study ID: NCT00302172
Interventions
Study Description
Brief Summary: To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 197.
Detailed Description: To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 197 given orally. This is an open label, dose escalation study of ARQ 197 administered orally at a starting dose of 10 mg bid (20 mg/day).
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Premiere Oncology, Santa Monica, California, United States
The Cleveland Clinic, Cleveland, Ohio, United States
Mary Crowley Medical Research Center, Dallas, Texas, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
